Double maintains 2 strategies that include ANIP - ANI Pharmaceuticals, Inc.
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| STG | -13.94% | $30.47M | -21.87% | 0.00% |
| DV | -13.43% | $2.45B | -23.79% | 0.00% |
| ICFI | -12.87% | $1.60B | -35.56% | 0.64% |
| LITB | -11.58% | $22.07M | -77.41% | 0.00% |
| ACHC | -11.55% | $2.16B | -64.47% | 0.00% |
| CBOE | -9.47% | $24.29B | +35.36% | 1.09% |
| TKC | -7.70% | $5.42B | -18.59% | 5.18% |
| K | -7.50% | $27.71B | +40.85% | 2.85% |
| UUU | -6.67% | $6.98M | +97.39% | 0.00% |
| HUSA | -5.66% | $21.26M | -8.69% | 0.00% |
| CNC | -5.30% | $28.19B | -14.41% | 0.00% |
| LTM | -5.18% | $12.31B | -95.54% | 2.46% |
| VZ | -4.74% | $184.17B | +6.28% | 6.15% |
| KMB | -4.69% | $43.67B | -4.62% | 3.76% |
| PRPO | -4.66% | $16.51M | +118.40% | 0.00% |
| VSTA | -4.03% | $341.66M | +42.00% | 0.00% |
| NEUE | -3.99% | $61.16M | +29.25% | 0.00% |
| HCA | -3.17% | $93.71B | +21.84% | 0.73% |
| SRRK | -3.15% | $3.21B | +342.46% | 0.00% |
| VSA | -3.09% | $8.76M | -18.25% | 0.00% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ORGO | 49.93% | $479.51M | +42.11% | 0.00% |
| BLX | 43.81% | $1.49B | +31.32% | 5.55% |
| BCO | 43.19% | $3.90B | -8.44% | 1.06% |
| PRGO | 41.57% | $3.77B | +5.54% | 4.10% |
| MTRN | 40.97% | $1.70B | -22.87% | 0.66% |
| IOSP | 40.56% | $2.17B | -28.88% | 1.86% |
| REAL | 40.51% | $560.95M | +53.09% | 0.00% |
| PAR | 40.23% | $2.71B | +44.60% | 0.00% |
| ADMA | 40.12% | $4.27B | +56.84% | 0.00% |
| OCUL | 39.84% | $1.45B | +36.23% | 0.00% |
| TREX | 39.59% | $6.18B | -20.54% | 0.00% |
| GFF | 39.44% | $3.57B | +17.46% | 0.91% |
| RCUS | 39.17% | $885.20M | -42.94% | 0.00% |
| CBT | 39.15% | $4.19B | -12.84% | 2.23% |
| IMNM | 39.08% | $736.56M | -27.65% | 0.00% |
| AZZ | 39.07% | $2.90B | +28.35% | 0.70% |
| KFY | 38.87% | $3.84B | +9.01% | 2.17% |
| GCI | 38.51% | $538.88M | -23.33% | 0.00% |
| TRIP | 38.51% | $1.82B | -21.77% | 0.00% |
| LGND | 38.48% | $2.17B | +32.75% | 0.00% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| MLN | -0.01% | $540.39M | 0.24% |
| YEAR | -0.06% | $1.47B | 0.25% |
| JSI | 0.09% | $865.26M | 0.49% |
| TDTT | 0.19% | $2.63B | 0.18% |
| TLH | -0.21% | $11.41B | 0.15% |
| NUBD | 0.26% | $396.52M | 0.16% |
| SUSB | 0.28% | $987.13M | 0.12% |
| USDU | -0.31% | $163.19M | 0.5% |
| VGLT | 0.35% | $9.76B | 0.04% |
| STXT | -0.42% | $128.98M | 0.49% |
| FLCB | -0.46% | $2.59B | 0.15% |
| SMB | -0.49% | $274.79M | 0.07% |
| SCHQ | 0.55% | $752.08M | 0.03% |
| GSST | 0.57% | $919.83M | 0.16% |
| FMHI | 0.58% | $753.22M | 0.7% |
| PYLD | 0.70% | $5.85B | 0.69% |
| DBE | 0.71% | $52.32M | 0.77% |
| SPTL | 0.72% | $11.23B | 0.03% |
| JBND | 0.74% | $2.31B | 0.25% |
| TFLO | -0.75% | $6.83B | 0.15% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| VIXY | -31.66% | $165.58M | 0.85% |
| TAIL | -31.16% | $99.49M | 0.59% |
| BTAL | -25.13% | $295.67M | 1.43% |
| ULST | -23.14% | $658.54M | 0.2% |
| IVOL | -17.91% | $348.25M | 1.02% |
| FTSD | -14.58% | $231.68M | 0.25% |
| XONE | -13.05% | $585.85M | 0.03% |
| SPTS | -12.57% | $5.77B | 0.03% |
| SCHO | -12.00% | $11.46B | 0.03% |
| IBTG | -11.99% | $1.92B | 0.07% |
| LDUR | -11.84% | $929.45M | 0.5% |
| VGSH | -11.24% | $22.77B | 0.03% |
| UTWO | -10.81% | $379.27M | 0.15% |
| IBTH | -10.71% | $1.60B | 0.07% |
| IBTI | -9.14% | $1.06B | 0.07% |
| BILS | -9.04% | $3.83B | 0.1356% |
| CTA | -7.43% | $1.06B | 0.76% |
| IEI | -7.11% | $15.41B | 0.15% |
| BUXX | -7.03% | $324.81M | 0.25% |
| SHY | -7.02% | $23.96B | 0.15% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| RVLV | 0.01% | $1.52B | +36.83% | 0.00% |
| EXEL | -0.15% | $11.90B | +96.93% | 0.00% |
| TAK | 0.22% | $48.37B | +17.96% | 4.32% |
| DAO | 0.24% | $269.33M | +135.25% | 0.00% |
| CASI | 0.26% | $20.61M | -75.42% | 0.00% |
| SMWB | 0.29% | $705.71M | +15.45% | 0.00% |
| ED | 0.29% | $36.31B | +13.27% | 3.35% |
| PULM | 0.33% | $24.14M | +230.50% | 0.00% |
| CYCN | 0.43% | $9.95M | +33.33% | 0.00% |
| PSQH | 0.47% | $97.45M | -38.51% | 0.00% |
| SAVA | -0.49% | $89.37M | -84.31% | 0.00% |
| KEP | 0.52% | $17.64B | +95.17% | 0.57% |
| HSY | 0.68% | $35.62B | -4.79% | 3.11% |
| NOC | -0.72% | $72.47B | +15.13% | 1.72% |
| MOH | 0.72% | $16.60B | +4.89% | 0.00% |
| PG | 0.73% | $377.99B | -1.64% | 2.53% |
| PARAA | -0.74% | $15.30B | +17.49% | 0.88% |
| CME | 0.85% | $99.25B | +39.75% | 3.87% |
| PDD | -0.86% | $146.50B | -21.21% | 0.00% |
| AMRC | 0.88% | $837.45M | -40.82% | 0.00% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| PTH | 49.25% | $100.70M | 0.6% |
| XBI | 46.72% | $4.84B | 0.35% |
| IWO | 45.76% | $11.53B | 0.24% |
| IWC | 45.54% | $817.74M | 0.6% |
| ARKG | 45.18% | $1.02B | 0.75% |
| VTWO | 44.57% | $12.58B | 0.07% |
| IWM | 44.56% | $63.18B | 0.19% |
| GSSC | 44.07% | $560.96M | 0.2% |
| PSC | 43.70% | $749.89M | 0.38% |
| GNOM | 43.50% | $44.38M | 0.5% |
| XPH | 43.40% | $148.46M | 0.35% |
| XSMO | 43.38% | $1.68B | 0.39% |
| IJT | 43.30% | $6.06B | 0.18% |
| SCHA | 43.25% | $17.26B | 0.04% |
| KJUL | 43.20% | $119.28M | 0.79% |
| SLYG | 42.84% | $3.40B | 0.15% |
| IWMY | 42.83% | $118.77M | 1.02% |
| IWN | 42.57% | $10.93B | 0.24% |
| KJAN | 42.55% | $287.49M | 0.79% |
| USVM | 42.54% | $951.98M | 0.3% |
Yahoo
PRINCETON, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, will host 1x1 meetings at the Leerink Partners Therapeutics Forum: I&I and Metabolism on Tuesday, July 8, 2025, in Boston, MA. About ANI Pharmaceuticals, Inc. ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives"
Finnhub
ANI Pharmaceuticals, Inc. dropped from Russell 3000 Value Index...
Finnhub
ANI Pharmaceuticals, Inc. added to Russell 2000 Growth-Defensive Index...
Finnhub
ANI Pharmaceuticals, Inc. dropped from Russell 2500 Value Index...
Yahoo
ANI Pharmaceuticals' first quarter results were marked by substantial top-line growth, but the market responded negatively, with shares falling sharply after the report. Management attributed the quarter’s revenue strength to a surge in generics sales, ongoing robust demand for Cortrophin Gel, and increased activity in branded products. CEO Nikhil Lalwani said, “The first quarter reflected particularly strong performance for our generics business, continued solid demand for Cortrophin Gel, and i
Finnhub
ANI Pharmaceuticals, Inc. added to Russell 2000 Defensive Index...
Current Value
$63.631 Year Return
Current Value
$63.631 Year Return
